Status:

TERMINATED

A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses

Lead Sponsor:

MedImmune LLC

Conditions:

Healthy Volunteers

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

This is a 6-part study to evaluate the safety, tolerability, and PK of MEDI7219 in healthy subjects. Parts A, B, C \& E are the single-dose parts of the study. Parts D \& F are the multiple ascending ...

Detailed Description

MEDI7219 is being developed for the potential treatment of type 2 diabetes. The study is a first in human, single and multiple ascending dose study that will try to identify the safety, tolerability a...

Eligibility Criteria

Inclusion

  • Healthy volunteers age 18-55 years
  • BMI 18-32 kg/m2
  • Females not of childbearing potential
  • Able and willing to adhere to the protocol
  • Must provide written informed consent

Exclusion

  • Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product
  • Abnormal lab values, physical exam, vital signs
  • Positive drug or alcohol screen.
  • Current enrollment in another clinical study or enrollment within the past 3 months
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to dosing
  • Abnormal ECG
  • Positive Hepatitis B, Hepatitis C or HIV test
  • Positive Drug or Alcohol screen
  • Current smokers or those who have smoked within the last 12 months
  • Recent plasma or blood donation
  • Evidence of current SARS-CoV-2 infection (Part E Cohort 5 and Part F Cohort 2 only)

Key Trial Info

Start Date :

December 4 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 11 2020

Estimated Enrollment :

186 Patients enrolled

Trial Details

Trial ID

NCT03362593

Start Date

December 4 2017

End Date

May 11 2020

Last Update

August 31 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Research Site

Ruddington, United Kingdom, NG11 6JS